Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Robert Q. Le; Kamar Godder; Jingyan Wang; Justin S. Collazo; Robyn Konicki; Moran Choe; Monica Feng; Donna Przepiorka; Jonathon Vallejo; Ankit Shah; Jiang Liu; Brenda J. Gehrke; Willie Wilson; Andrea Siegel; Yun Wu; Charles Yuan-Chia Kuo; Melissa Ray; Richard Pazdur; Marc R. Theoret; R. Angelo de Claro

doi:10.1158/1078-0432.30029288

Key Points

The analysis illustrates time to adverse events of special interest (AESIs) with axatilimab treatment in chronic GVHD.
Findings indicate that chronic GVHD patients, after two prior lines of systemic therapy, benefit from receiving axatilimab for improved management.
The data includes both adult and pediatric patient outcomes, providing a comprehensive view of treatment effectiveness.
Understanding these timeframes may guide future therapeutic decisions for patients struggling with chronic GVHD.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supplementary figure reveals time to adverse events of special interest in chronic GVHD treatment, highlighting outcomes in both adult and pediatric patients.

Abstract

Graphs of time to AESIs

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Le et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5df https://doi.org/10.1158/1078-0432.30029288

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading